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Abstract
Background: Heterozygous mutations in OPA1 are a common cause of autosomal dominant optic atrophy,
sometimes associated with extra-ocular manifestations. Few cases harboring compound heterozygous OPA1
mutations have been described manifesting complex neurodegenerative disorders in addition to optic atrophy.
Results: We report here three patients: one boy showing an early-onset mitochondrial disorder with hypotonia,
ataxia and neuropathy that was severely progressive, leading to early death because of multiorgan failure; two
unrelated sporadic girls manifesting a spastic ataxic syndrome associated with peripheral neuropathy and, only in
one, optic atrophy. Using a targeted resequencing of 132 genes associated with mitochondrial disorders, in two
probands we found compound heterozygous mutations in OPA1: in the first a 5 nucleotide deletion, causing a
frameshift and insertion of a premature stop codon (p.Ser64Asnfs*7), and a missense change (p.Ile437Met), which
has recently been reported to have clinical impact; in the second, a novel missense change (p.Val988Phe) co-
occurred with the p.Ile437Met substitution. In the third patient a homozygous mutation, c.1180G > A (p.Ala394Thr)
in OPA1 was detected by a trio-based whole exome sequencing approach. One of the patients presented also
variants in mitochondrial DNA that may have contributed to the peculiar phenotype.
The deleterious effect of the identified missense changes was experimentally validated in yeast model. OPA1 level
was reduced in available patients’ biological samples, and a clearly fragmented mitochondrial network was
observed in patients’ fibroblasts.
Conclusions: This report provides evidence that bi-allelic OPA1 mutations may lead to complex and severe multi-
system recessive mitochondrial disorders, where optic atrophy might not represent the main feature.
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Background
Optic Atrophy 1 (OPA1, OMIM*605290) is a dynamin-
related protein of the large GTPase superfamily that lo-
cates to the inner mitochondrial membrane and is
involved in mitochondrial dynamics and mtDNA
maintenance.
Pathogenic mutations in the OPA1 gene have largely
been associated with autosomal dominant optic atrophy
(ADOA; OMIM#165500), a visual disorder associated
with degeneration of retinal ganglion cells. Its prevalence
is estimated at 1/50,000. Classical ADOA typically has
early onset, before 10 years of age, and manifests with
various levels of visual impairment: bilateral visual loss,
dyschromatopsia, centrocecal scotomas and temporal
optic disc atrophy. Up to 20% of OPA1-mutated patients
also develop additional more complex neurodegenerative
disorder with extra-ocular manifestations, including
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deafness [1], chronic progressive external ophthalmople-
gia, ptosis, ataxia, peripheral neuropathy and mitochon-
drial myopathy with multiple mtDNA deletions, leading
to a syndromic disease sub-group known as ‘ADOA plus’
(OMIM#125250) [2, 3].
To date, over 300 mutations in OPA1 have been
identified and associated with ADOA and ADOA plus.
Half of these variants are predicted to result in a trun-
cated protein producing haploinsufficiency and are
usually linked to the classical non-syndromic form of
ADOA. The ‘ADOA plus’ phenotype is often associated
with dominant missense mutations in OPA1 [1]. In a
few cases, the phenotype is due to compound hetero-
zygous OPA1 mutations preserving transcript expres-
sion [3], and suggestive of recessive or semi-dominant
patterns of inheritance [3–5]. Recently, compound het-
erozygous mutations in OPA1 have been associated
with Behr syndrome (OMIM#210000), a disease char-
acterized by the association of early-onset optic atro-
phy with spinocerebellar degeneration [6, 7]. Finally,
the first homozygous OPA1 mutation has just been re-
ported, associated with fatal infantile mitochondrial
encephalomyopathy, hypertrophic cardiomyopathy and
optic atrophy [8]. The clinical spectrum of these emer-
ging double-mutant OPA1-related disorders remains to
be fully characterized.
We report here three patients with biallelic OPA1 mu-
tations: a boy showing an early-onset and severely pro-
gressive mitochondrial disorder and two girls showing a
spastic ataxic syndrome associated with sensory motor
peripheral neuropathy, resembling Behr syndrome.
Methods
Molecular genetics
Total DNA was extracted from muscle, peripheral blood
lymphocytes, fibroblasts from patients and relatives
using standard methods. Sequencing of the entire mito-
chondrial DNA (mtDNA) was performed essentially as
previously described [9]. mtDNA content was evaluated
by real-time PCR-based quantification (ABI7000 Real-
Time PCR System) using specific mtDNA probes
(amplicons nt 867-928, 12835-12893) and a standard,
single-copy autosomal gene (RNaseP) [10].
For Patients1 and 2, NGS library preparation, sequen-
cing, alignment and variant calling were performed as
recently described [11]. Filtering was carried out by ap-
plying a series of steps: low-quality variants were filtered
out (Illumina Qscore threshold of 20); variants with a
minor allele frequency (MAF) >1% in the 1000 Genomes
Project (http://www.1000genomes.org), Exome Variant
Server (http://evs.gs.washington.edu) and Exome Aggre-
gation Consortium (ExAC: http://exac.broadinstitu-
te.org) databases were discharged; finally, we focused on
predicted missense, frame-shift, stop-gain or stop-loss,
and splice-site variants.
For proband 3, targeted enrichment and massively
parallel sequencing were performed on genomic DNA
of the affected subject and their parents. Exome cap-
ture was carried out using SureSelect Human All Exon
V.4 (Agilent). Sequencing data analysis was performed
using an in-house implemented pipeline which mainly
takes advantage of the Genome Analysis Toolkit
(GATK V.3.5) framework [12], as previously reported
[13–15]. Quality filtering of variants were as previously
reported [16], and high-quality variants were filtered
against public (dbSNP146 and ExAC V.0.3) and in-
house (approx. 600 population-matched WES) data-
bases to retain private, rare (MAF <0.1%) and clinically
associated variants, which were filtered to retain only
those located in exons with any effect on the coding
sequence, and splice site regions (variants located from
−3 to +8 with respect to an exon-intron junction).
Functional annotation of variants was performed
using SnpEff V.4.2 and dbNSFP V.2.9 [17–19]. WES
statistics are reported in Additional file 1. Functional
impact of variants was analyzed by Combined Annota-
tion Dependent Depletion (CADD) V.1.3 and dbNSFP
Support Vector Machine (SVM) V.2.9 algorithms [18,
19]. Variant prioritization was performed by GeneDis-
tiller [20]. All variants identified by NGS were vali-
dated by Sanger sequencing.
RNA was extracted from skin fibroblasts and 1 μg was
used as template for reverse transcriptase PCR (RT-
PCR) to obtain full-length cDNA. OPA1 transcript was
amplified and PCR products were sequenced in order to
confirm genomic variants and unmask potential events
of nonsense mediated decay.
Yeast studies
A hybrid gene was obtained by joining the 5' portion of
the yeast MGM1 gene (the orthologous of human
OPA1), encoding the mitochondrial targeting sequence
and the transmembrane domain, to the 3' of the human
OPA1 cDNA using a sequential PCR protocol. Primers
and conditions are available upon request. The resulting
construct was then cloned into the pCM184 yeast ex-
pression vector. Individual mutants were generated by
site-specific mutagenesis.
Yeast strains, media, growth conditions, and the whole
procedure for selection of haploid cells have been previ-
ously reported in detail [21]. Briefly, a single copy of the
MGM1 gene was inactivated in wild type diploid W303
yeast by homologous recombination with a KANMX4
cassette. Heterozygous strains were transformed with ei-
ther the wild type or one of the mutant constructs and,
after sporulation, haploid yeast harboring the mutant
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MGM1 gene and the plasmid of interest were selected
and used for subsequent experiments.
Immunoblot analyses
Fibroblasts were pelleted and solubilized in RIPA buffer
with protease inhibitors. 50 μg of proteins were loaded
for each sample in 10% denaturing sodium-dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE).
The following antibodies were used: OPA1 (monoclonal
antibody BD Biosciences), NDUFA9 (MitoSciences),
MTCO2 (MitoSciences), porin/VDAC (MitoSciences),
beta-tubulin/TUBB (Sigma-Aldrich), and HSP60 (Abcam).
Fluorescence microscopy
Skin fibroblasts from patients and controls were cul-
tured in a 37 °C incubator with 5% CO2, in either
25 mM glucose or 5 mM galactose DMEM (Euroclone)
supplemented with 10% FBS, 1% L-glutamine, and 0.2%
sodium pyruvate. For visualization of the mitochondrial
network, the mitochondrial fluorescent dye MitoTracker
Red-CMXRos (Invitrogen) was added to the culture
media at final concentrations of 50 nM for 30 min and
then visualized by fluorescence microscopy. Images for
P1 were acquired with a confocal microscope (Leica
TSC-SP8) and for P3 with inverted microscope (Leica
DMi8).
Biochemical studies
Complex V activity was measured in fibroblast mito-
chondria of P3 and age-matched controls, using reported
spectrophotometric methods [22]. Either succinate (the
direct substrate of complex II-succinate dehydrogenase),
or malate and pyruvate +malate (which generate NADH,
substrate of complex I-NADH dehydrogenase) were
used as substrates. Cellular ATP content was assayed
luminometrically using the ATPLite 1 Step (PerkinElmer,
Boston) according to the procedure recommended by
the manufacturer and using 2 × 104 cells. Aged matched
controls have been used in three different experiments,
either in a regular medium as well as in a galactose-
supplemented medium (5 mM). Luminescence was
measured using the EnSpire Multimode Plate Readers
(PerkinElmer).
Electrophysiology studies
Electroretinogram (ERG): Retimax instrument (CSO, Fi-
renze, Italy) was used for the full-field flash ERG and
pattern VEP assessment in the protocol session. The
cornea was anesthetized with 1% dicaine. HKloops ring
fiber electrodes were used to record ERGs. A small Ag/
AgCl skin earth electrode was placed at the center of the
forehead. Mesopic and photopic stimuli were used for
recording sessions.
Visual evoked potential (VEP): Visual stimuli consisted
of checkerboard patterns (a single check edge subtend-
ing 60 and 15 min of arc; contrast 99%; mean luminance
60 cd/m2) generated on a monitor subtending 26° and
reversed in contrast at the rate of two reversal per sec-
ond. The stimulation was monocular, with full occlusion
of the fellow eye. To maintain stable fixation, a small red
target was (0.5°) was placed in the center of the stimula-
tion field. VEPs were recorded by cup-shaped Ag/AgCl
electrodes placed over the scalp two cm above the inion
(Oz) with the reference in Fpz and the ground on the
mastoid. The time-to-peak (in milliseconds) and peak-
to-peak amplitude (in microvolts) of major VEP compo-
nents (i.e. N75, P100 and N145) were measured.
Optical coherence tomography (OCT)
Peripapillar retinal nerve fiber layer (RNFL) thickness
was measured with a spectral-domain (SD)-OCT (Optos
SD-OCT, Glasgow, UK). All scans were done using an
internal fixation target in the OCT device. The fast
RNFL scan protocol consisted of three consecutive 360°
circular scans with a diameter of 3.4 mm centered on
the optic disc. Parameters including average RNFL thick-
ness in four quadrants were generated automatically in
the analysis report and compared to control values. Each
sector was coded in green, yellow, or red for RNFL
measurement greater than the lower 95th percentile, less
than the lower 95th percentile, or less than the lower
99th percentile range, respectively. All images had signal




P1. The proband P1 (II-2) is a boy, second child from
unrelated parents.
His older brother (II-1) was affected by a neurological
disease for which a metabolic etiology was suspected but
never confirmed. In II-1, psychomotor delay was re-
ported since first age of life, and he never achieved sit-
ting or standing position. At 9 months of age the
presence of ptosis and ophthalmoparesis was depicted,
with normal fundus exam. Neurological evaluation at
the age 2.5 years showed poor somatic growth (10%ile),
microcephaly (<3%ile), hypotonia, ataxia and mental re-
tardation. The following exams resulted normal: plasma
lactate, organic acids, amino acids, mucopolysaccharides,
oligosaccharides; no brain MRI was available. The sibling
II-1 died at age 2 years and 10 months with multiorgan
failure during a septic shock due to paralytic ileus. No
biological material was available from this individual.
P1 presented since first months with frequent vomiting
and marked psychomotor delay: head control was ac-
quired at 10 months, sitting at 2.5 years, standing at 5 years
Nasca et al. Orphanet Journal of Rare Diseases  (2017) 12:89 Page 3 of 10
and first words at 3 years of age. He was firstly evaluated
at 4 years in another Hospital because of myoclonic epi-
leptic seizures. Clinical examination showed a severe
neurological impairment, characterized by absence of
head control, poor eye contact and response to sounds,
presence of nystagmus, and absence of language. Brain
MRI (not available) depicted symmetrical hyperintense al-
terations in the putamina, cerebellar atrophy and presence
of oedema in the occipito-parietal cortical areas. EEG
showed poor organization of cerebral activity with the
presence of sharp waves in occipital regions. Lactate levels
were elevated in plasma (2800 mmol/L) and in CSF; the
analysis of respiratory chain complexes and PDH complex
on muscle biopsy resulted normal. The neurological con-
ditions were subsequently referred stable, with good con-
trol of epilepsy, left hemiparesis and severe mental
impairment. Fundoscopic examination at 5 years showed
the presence of optic atrophy. At the age of 8 years, fol-
lowing an accidental head trauma, he developed an acute
psychomotor regression; 5 months later was admitted to
our Institute, showing poor height and growth, scarce re-
sponse to pain stimuli, absence of postural control,
marked hypotonia and absence of spontaneous move-
ments. Hepatic function was markedly impaired; lactate
and pyruvate levels were normal. EEG revealed the pres-
ence of theta-delta asymmetric activity (depressed on right
hemisphere). Brain MRI showed the presence of bilateral,
marked and swollen alterations in the mesencephalon,
pons and subthalamic nuclei (Fig. 1a, b), associated with
necrosis of putamina, and partially in caudate nuclei
(Fig. 1c), thin corpus callosum, ventricular enlargement
and mild cerebellar atrophy (Fig. 1a, d); the presence of a
cortical abnormality in the parietal and occipital right re-
gions was also present. H-MRS showed a very high lactate
peak, both in the abnormal and in the spared areas. A sec-
ond MRI performed after 20 days was unchanged. Neuro-
physiological study showed the presence of severe axonal
sensory neuropathy (absence of Sensory Action Potentials
- SAPs, and normal Motor nerve Conduction Velocity -
MCV, with mild reduction of Compound Muscle Action
Potentials - CMAPs). Respiratory chain complexes and
PDH complex activities resulted normal in muscle and fi-
broblasts. In the following days he developed respiratory
failure requiring artificial ventilation and subsequently a
dc
ba
Fig. 1 MRI findings of proband 1. a, b: sagittal and axial T2-weighted sections showing the presence of bilateral hyperintense alterations in the
mesencephalon, pons and subthalamic nuclei, all markedly swollen; c: axial T2-weighted image showing bilateral necrosis of putamina and left
caudate nuclei; d: coronal T1-weighted image showing cerebellar atrophy, dentate nuclei hyperintensity and ventricular enlargement
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severely progressive impairment of clinical conditions with
sepsis and a multiorgan failure leading to decease. Parents
refused autopsy. Neurological and neuro-ophthalmological
evaluations were normal in both parents.
P2. The proband P2 is the only child of unrelated par-
ents of Italian origins. Family history was negative:
mother presents severe myopia without optic atrophy or
any neurological sign. P2 was born at term after an un-
complicated pregnancy and delivery. Psychomotor devel-
opment was referred normal. Between ages 4 and
6 years, she presented worsening of her visual acuity. Bi-
lateral optic neuropathy was diagnosed with normal
ERG but altered VEPs. She underwent to ophthalmo-
logic follow-up (instrumental data not available). She ar-
rived at our observation at 14 years of age. Neurological
evaluation showed mild bilateral ptosis and strabismus,
dysdiadochokinesia, dysmetria, mild ataxia and pes
cavus; tendon reflexes were absent. Cognitive functions
were normal. Fundoscopy and VEPs confirmed optic at-
rophy; ERG was normal; SAPs and BAEPs showed cen-
tral conduction abnormalities. Brain MRI disclosed optic
nerves and chiasm atrophy. Electroneuronography re-
vealed an axonal sensory neuropathy. Electroencephal-
ography was normal. Plasmatic lactate levels were
normal. Treatment with idebenone (135 mg/die) was
started. Neurological and ophthalmologic follow-up, six
months after diagnosis, were stable.
P3. The proband P3 is a 12 year old girl, who was born
at term by dystocic delivery; she was the second child of
healthy consanguineous parents. The eldest brother was
healthy. She acquired autonomous ambulation at
14 months of age, but parents reported that she had al-
ways been unsteady, and had delayed speech develop-
ment. At 4 years she began to present psychomotor
regression, ataxia and deficient motor coordination. At
4 years the neurological examination showed an ataxic-
spastic gait, nystagmus, dysmetria and dysarthria. She
performed a first brain MRI which showed abnormal
hyperintensities of the periventricular and centrum
semiovale white matter areas in T2-weighted images bi-
laterally (Additional file 2). Electrophysiological exami-
nations showed bilateral absence of the V wave at
Brainstem Auditory Evoked Potentials (BAEPs), and
Nerve Conduction Studies (NCS) disclosed an axonal
sensory-motor neuropathy (decreased CMAP and SAP
amplitudes with conduction velocities at the lower level
of controls range). Phytanic and pristanic acids, VLCFA,
Vitamin E, hexosaminidase A and B levels were in the
normal range. One year later, the neurological conditions
worsened with increased spasticity in her legs and un-
steadiness during walking and postural changes. NCS
showed a progressive decrease of CMAP amplitudes
compared to previous values; VEP and ERG were nor-
mal. A second MRI performed at 8 years of age showed
T2-hyperintense abnormal signals corresponding to both
putaminal nuclei, associated with mild global cerebellar
atrophy, while the abnormal areas of T2 hyperintensities
of the white matter had disappeared (Additional file 2).
Mutations in FXN, ATM and PLA2G6 were ruled out by
Sanger sequencing. At age 10 years the neurological
examination was stable; repeated flash VEP showed
slightly delayed latencies bilaterally, whereas OCT was
reported as normal. The last neurological evaluation at
age 12 years showed an ataxic-spastic syndrome with
distal muscular atrophy of upper and lower limbs. A
deep ophthalmological examination was performed:
OCT revealed a mild reduction of retinal nerve fiber
layer in both eyes whereas flash ERG and pattern
VEP responses (60’ stimuli) were in the normal range.
However, an amplitude reduction of VEP response
was found for 15’ stimuli: abnormalities in VEP 15’
responses, which mainly reflect macular fibers re-
sponses contributing to the temporal quadrant of the
optic nerve, are quite typical of OPA1- related optic
neuropathy (Additional file 3).
Genetic studies
Because of the clinical presentation suggesting a mito-
chondrial disorder, we first investigated the mitochon-
drial DNA (mtDNA) in our proband P1. The complete
sequencing of mtDNA revealed the presence of two
homoplasmic variants: the m.11778G > A change in
MTND4, known to be associated with Leber’s hereditary
optic neuropathy (LHON), and the m.3337G > C change
in MTND1. The latter is expected to cause the p.Val11-
Leu substitution, affecting a poorly conserved amino
acid residue (with leucine present in chicken). Bioinfor-
matics tools for pathogenicity predicted a neutral effect
for this amino acid change. Both variants were homo-
plasmic also in the mother’s DNA. The quality/quantity
of the DNA extracted from the proband’s muscle was
not enough to perform Southern blot analysis. Since the
LHON mutation was unlikely the main cause of the dis-
ease in P1, his DNA was subjected to targeted resequen-
cing of a panel containing >100 nuclear genes associated
with mitochondrial disorders. After filtering steps to re-
move common polymorphisms (>1% in public database)
and variants with probably neutral effect (synonymous
changes, intronic variants >20 bases far from exons), 6 var-
iants remained. Because the pedigree was suggestive for a
recessive trait, we focused on the only gene with bi-allelic
variants: OPA1. Two heterozygous calls were present: a 5
nucleotide deletion c.190_194del (NM_130837.2), predict-
ing a truncated protein product (p.Ser64Asnfs*7), and a
previously annotated missense c.1311A >G change
(p.Ile437Met). Direct sequencing validated the two variants
and confirmed their occurrence in trans, with the missense
change on the maternal allele and the frame-shift change
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on the paternal allele (Fig. 2a). The c.190_194del was ab-
sent in public variant databases, whereas the c.1311A >G
change is reported with a frequency of 0.06% in ExAc data-
base. The latter corresponds to c.1146A >G, p.I382M
based on transcript NM_015560.2, used in the past as ref-
erence isoform, and has been already reported in other bi-
allelic cases [5, 23].
Targeted sequencing and variant filtering in P2 led to
the identification of two heterozygous OPA1 variants:
c.2962G > T (p.Val988Phe), and the recurrent c.1311A >
G substitution (p.Ile437Met). Both variants were con-
firmed by Sanger sequencing; the mother harbored the
c.1311A > G, the paternal DNA was not available for
genotyping (Fig. 2b).
In P3 data annotation of WES data predicted 13229
high-quality variants having functional impact (i.e., non-
synonymous, indels and splice site changes). Among
them, 338 private and rare changes were retained for
further analyses. Variants were prioritized on the basis of
the functional relevance of genes, taking into account
both dominant and recessive inheritance models. Only
changes predicted to be deleterious by CADD V.1.3
(score >15.0) or dbNSFP SVM V.2.9 (radial score >0.0)
algorithms were considered as candidates. Variant filtering
and prioritization allowed to identify a missense homozy-
gous variant in OPA1, c.1180G >A (NM_130837.2), pre-
dicting the p.Ala394Thr amino acid substitution, as the
best candidate underlying the trait, which fitted with the
documented consanguinity in the family (Fig. 2c). Consist-
ently, no suggestive disease gene candidate with a func-
tionally relevant de novo heterozygous variant was
identified in the proband (Additional file 1).
Yeast studies
Yeast lacking MGM1 cannot grow on non-fermentable
carbon sources and develop a petite phenotype [24]. Hu-
man OPA1 per se cannot complement yeast MGM1 de-





Fig. 2 Genetic and yeast studies. a, b, c: Pedigrees and electropherograms showing the mutations found in this study: families of proband P1
(panel a), proband P2 (panel b) and proband P3 (panel c). d: Strains lacking MGM1 and transformed with either wt OPA1 hybrid allele or
individual mutants p.Ala394Thr, p.Val988Phe, p.Ile437Met or empty vector were grown on YP medium supplemented with glycerol. Cells were
plated after serial dilutions. Picture was taken after 4 days of growth. Numbering of amino acids in the yeast hybrid genes refers to the corresponding
human counterpart (NM_130837.2; NP_570850.2)
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gene comprised of the 5’ portion of MGM1 (encoding
the targeting sequence and the transmembrane domain)
and the 3’ portion of human OPA1 (from exon 6 to the
stop codon). Haploid yeast lacking MGM1 and express-
ing either the wild-type hybrid gene or individual mu-
tants, were plated at seriate dilutions in medium
containing glycerol as sole carbon source (YPD). The
wild type hybrid gene restored growth in YPD. Con-
versely, yeast expressing the p.Ala394Thr displayed a
marked reduction of respiratory growth, the p.Val988Phe
mutation virtually abolished the activity of the mutant
allele, while the defect observed with the p.Ile437Met
mutant was milder, evident only at the 10-3 dilution
(Fig. 2d).
Characterization of fibroblasts carrying OPA1 mutations
The OPA1 transcript levels, assessed by quantitative
RTPCR in P1, were comparable in patient’s and control
samples and cDNA sequencing indicated that the two
alleles were similarly expressed, excluding major mRNA
decay of the allele with the premature stop codon.
Nevertheless, Western blot analysis on whole cell lysates
of primary fibroblasts from P1 showed a clear reduction
in the amount of all OPA1 isoforms (Fig. 3a). Given the
known role of OPA1 in mitochondrial fusion, to evaluate
the functional consequences of the identified OPA1 vari-
ants we assessed the mitochondrial network in fibro-
blasts. Fibroblasts grown in either standard glucose- or
galactose-medium were stained with a mitochondrial
dye (Mitotracker Red) and examined by fluorescence mi-
croscopy. In patient’s cells we found increased fragmen-
tation of the mitochondrial network compared with
controls (Fig. 3b, Additional file 4), in agreement with
the expected reduced fusion caused by dysfunctional
OPA1. In addition to the role in mitodynamics, OPA1
has been reported to act in the maintenance of mito-
chondrial genome integrity [25]. In total DNA extracted




Fig. 3 Characterization of fibroblasts from proband 1. a: OPA1 protein amount in patient’s (P1) and control (CT1, CT2 and CT3) fibroblasts,
obtained using an anti-OPA1 antibody. Anti-TUBB and anti-HSP60 antibodies were used as loading controls. b: Representative images of mitochondrial
morphology (obtained with Mitotracker red) in fibroblasts from proband 1 (P1) and a control (CT), grown either in glucose or galactose medium. Scale
bar: 20 μm. c Quantification of mtDNA amount in fibroblasts (fb) and skeletal muscle (ms) from proband 1 (P1) and controls. (Ct). The bars represent
the amount of mtDNA normalized to nuclear DNA (nDNA), compared to the mean value of controls (=1). Two different probes for mtDNA were used.
Data are represented as mean + SD
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quantitative PCR. In P1, the mtDNA content was partly
but significantly lower than controls (≈40% of the mean
control value, Fig. 3c). Notably, the reduction in mtDNA
levels (≈35% of the mean control value) was confirmed
in DNA extracted from patient’s muscle (Fig. 3c). Simi-
larly, in P3 cells the amount of OPA1 was reduced and
the mitochondrial network appears fragmented; as for
P1, the latter phenomenon was more evident in medium
supplemented with galactose (Additional file 4 and Add-
itional file 5). In the fibroblasts mitochondria of P3 the
rate of ATP synthesis was found to be slightly reduced,
with respect to the control mean values, when succinate
was used, whereas a significant reduction was evident
when malate and pyruvate +malate were used as sub-
strates (Additional file 6A). The ATP content in P3 fi-
broblasts was normal respect to controls in regular
medium but significantly reduced in galactose medium
reflecting the lower efficiency of ATP production by
OXPHOS in stress condition (Additional file 6B). No
cells were available from P2.
Discussion
Compound heterozygous mutations in OPA1 have
been rarely reported, usually associated with ADOA
plus phenotype [5, 6, 7, 23, 26]. A table summarizing
genetic and clinical features of these cases is reported
as Additional file 7. The p.Ile437Met missense vari-
ant, although not causing a phenotype per se, has
been recently suggested to contribute consistently in
modulating the phenotype in OPA1 compound het-
erozygous subjects [23].
The biallelic OPA1 variants found in two of our pa-
tients combine a classic OPA1 haploinsufficiency muta-
tion (i.e. a frameshift change in P1 and a missense
change, acting as a null allele in yeast, in P2), which can
determine dominant isolated optic atrophy with reduced
penetrance, and the missense mutation p.Ile437Met,
considered hypomorphic or with very low potential
pathogenicity since apparently it was not able to lead to
clinical symptoms in heterozygous or even homozygous
state [23]. Instead, in P3 we found a homozygous
p.Ala394Thr change; this is the second case of homozy-
gous missense mutation in OPA1 reported to date, after
the description of a patient with a severe fatal cardiomy-
opathy associated with the p.Leu589Arg mutation [8].
In accordance with a recessive mode of inheritance, the
parents of our probands, each carrier of one heterozygous
OPA1 variant, displayed no symptoms, with the exception
of a mother harboring the p.Ile437Met variant and pre-
senting a severe myopia; this genotype-phenotype associ-
ation was previously reported [5]. Reduced penetrance of
dominant mutations, typical of ADOA, may also explain
the segregation in the families but it is unlikely given the
severe phenotype of these patients.
The effect of the missense mutations on growth of the
yeast model seems to correlate with the clinical presen-
tation in biallelic OPA1 mutant patients; the presence of
a virtually null allele (p.Val988Phe found in P2) plus a
mildly compromised allele (p.Ile437Met found in P1 and
P2) or the presence of a homozygous mutation with an
intermediate effect (p.Ala394Thr found in P3) probably
cause a similar overall impairment in OPA1 function,
resulting in the disease observed in our patients.
From a medical point of view, the most striking aspect
of this study is the extremely severe presentation of P1,
with an infantile lethal outcome. The same course was
reported in the older brother, albeit the genetic diagnosis
was not possible because of lack of available DNA. We
therefore cannot exclude the presence of a different gen-
etic defect that was the primary cause of the disease in
this subject, or even in our proband. However, the ex-
tensive genetic analysis with sequencing of >100 genes
associated with mitochondrial disorders makes unlikely
the latter hypothesis. It is possible that additional genetic
factor may have exacerbated the phenotype caused by
the OPA1 mutations. Interestingly, P1 showed two
homoplasmic changes in his mtDNA. The mutation
m.11778G > A in MTND4 is a well-known cause of
LHON, a mitochondrial disorder that leads to bilateral
subacute visual failure. Rarely patients harboring the
m.11778G > A show a LHON-plus phenotype; neverthe-
less visual impairment remains the most common pre-
senting feature, although neurologic features have been
documented in several cases, including movement disor-
ders, multiple sclerosis–like illnesses, peripheral neur-
opathy, and seizures [27]. Haplogroup J has been shown
to increase the penetrance of this mutation [28], but our
proband belonged to haplogroup T1. However, the low
penetrance of the m.11778G > A in females is compat-
ible with the homoplasmic status of the unaffected
mother. The other change found in mtDNA, m.3337G >
C/p.Val11Leu in MTND1, is not phylogenetically con-
served, is predicted benign but it is not present in Mito-
map database (http://www.mitomap.org). Valine 11 is
located at the beginning of the first α-transmembrane
helix of ND1 protein, and the change with leucine is not
predicted to alter the transmembrane domain. Despite
both mtDNA variants affected respiratory complex I, its
activity was normal in patient’s samples. All these con-
siderations did not suggest a primary pathogenic role for
the two identified mtDNA variants but did not exclude a
synergistic effect together with the OPA1 mutations,
worsening the clinical phenotype in our patient.
Amongst the published patients with biallelic OPA1
mutations (Additional file 7), the severe neonatal-onset
disorder characterized by severe optic atrophy, ataxia,
hypotonia, gastrointestinal dysmotility and dysphagia,
described in two siblings by Schaaf et al. [5], is the
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closest to the clinical presentation of P1 and his brother.
Conversely the phenotype reminiscent of the Behr syn-
drome, reported in 4 cases by Bonneau et al. [6], was
similar to that observed in P2 and P3. However, optic at-
rophy was evident in all the other OPA1-mutant sub-
jects, being often the first and main symptom; in
contrast, in our patients overt optic atrophy was ob-
served later compared to most of the other neurological
signs (P1 and P3) or not reported (P1’s brother and P3,
untill 10 years of age). Moreover, the rapidly progressive
course of P1 is reminiscent of Leigh syndrome rather
than of DOA-plus or Behr syndrome. Infantile lethal
outcome due to OPA1 mutations has been described for
the first time very recently: a homozygous OPA1 muta-
tion has been found in two sisters with fatal infantile
mitochondrial encephalomyopathy, hypertrophic cardio-
myopathy and optic atrophy [8]. No evidence of heart
involvement was reported in our patients, but a multior-
gan failure, including gastrointestinal and hepatic im-
pairment, was observed in P1, confirming that OPA1
proper functioning is crucial not only for the optic nerve
but also for several other tissues/organs. Clinical features
in P3 were particularly misleading for an OPA1 related
condition, with manifestations of early onset progressive
spastic ataxia and sensory motor polyneuropathy, in the
absence of optic atrophy. The MRI was likewise pecu-
liar, showing early MRI abnormal hyperintensities of
the white matter suggesting a leukodystrophy followed
serially by a disappearance of white matter abnormal-
ities and appearance of bilateral abnormalities in the
putamen.
Conclusions
Our report confirms the broad complexity in the pheno-
typic spectrum associated with recessive OPA1 muta-
tions that ranges from non-syndromic phenotypes
overlapping with those caused by dominant OPA1 muta-
tions to severe fatal encephalopathy resembling typical
mitochondrial diseases. Moreover, our findings suggest
that bi-allelic OPA1 mutations should be considered in
disorder where optic atrophy is not obvious (or even
absent).
OPA1 mutations should not be considered only for
dominant trait or only for optic atrophy phenotypes.
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